BiomEdit
Jacob Shields has a strong background in research and analytics, with a focus on statistics. Jacob has held multiple roles at Elanco, starting as a Graduate Intern in Statistics in 2013 and progressing to Senior Research Scientist in the Portfolio Analytics & Decision Sciences department. Jacob's work at Elanco includes conducting statistical analysis, developing analytics models, and providing consultancy services. Jacob has also worked as a Graduate Assistant and Tutor at Indiana University Bloomington, where they gained experience in statistical research and teaching. Additionally, Jacob has interned at Eli Lilly and Company, where they further developed their statistical skills. Jacob is currently working at BiomEdit as a Senior Research Scientist.
Jacob Shields completed their education in a chronological sequence. Jacob began their academic journey in 2004 at Lawrence Central High School, where they pursued an honors program. After graduating from high school in 2008, Jacob attended Indiana University Bloomington, where they earned a Bachelor of Science degree in Statistics and a Bachelor of Arts degree in Economics, both obtained in 2012. Following their undergraduate studies, they continued their education at the same institution and obtained a Doctor of Philosophy degree in Statistical Science in 2017.
In addition to their formal education, Jacob obtained certifications in Lean Six Sigma Green Belt from Purdue University in December 2021 and in Strategic Portfolio Decisions from The University of Texas at Austin's Red McCombs School of Business in December 2018.
This person is not in any offices
BiomEdit
BiomEdit is an innovation company that discovers, designs, and develops novel probiotics, microbiome derived bioactives, and engineered microbial medicines to address unmet needs in animal health. Our ambition is to create solutions to some of the most important problems in animal agriculture and food security by leveraging the potential of themicrobiome. BiomEdit’s technology is based on a unique platform that utilizes high-throughput sequencing and data analytics to rapidly discover and screen novel probiotic species and bioactive molecules. These can then be engineered to confer thermostability, enhanced production of beneficial metabolites, or expression of immune modulating proteins. These probiotics and microbially-derived compounds represent the next generation of products designed to promote animal health without the use of antibiotics.